Lantern Pharma just posted a reminder that CEO Panna Sharma will participate in tomorrow’s BIO2026 executive roundtable hosted by Polsinelli.
What caught my attention is that management is actively promoting the event instead of quietly attending.
At a $50M market cap, Lantern is trying to position itself at the intersection of:
* Precision oncology
* AI-driven drug development
* RADR / withZeta
Not suggesting news is coming.
But if management believes these platforms are meaningful value drivers, BIO seems like an important venue to increase visibility among potential partners, investors, and industry leaders.
Am I the only one watching this?